Dr. Reddy's Laboratories Ltd.

BSE: DRREDDY500124ISIN INE089A01031

Healthcare
Pharmaceuticals
BSE 100

BSE listing

Share price

₹1,171.10-0.95 (-0.08%)

as of 18 Sep 2026

52W high: ₹1,414.40
52W low: ₹1,080.05
Off 52W high: -17.20%
1M return: +0.01%
3M return: -7.90%
6M return: -9.84%
1Y return: -11.44%
20D avg volume: 84,604
50 DMA: ₹1,177.50
200 DMA: ₹1,249.66

Key ratios Consolidated

Market cap: ₹97,745 Cr
Current price: ₹1,171.10
52W high / low: ₹1,414.40 / ₹1,080.05
Face value: ₹1.00
P/E: 30.71
P/B: —
EPS (TTM): ₹38.14
Book value / share: —
ROE: —
ROCE: 13.90%
Operating margin: —
Net margin: —
Debt / equity: 0.16
Net debt: ₹4,757 Cr
Interest cover: 15.39
Dividend yield: 0.68%
Dividend / share (TTM): ₹8.00
Payout: 20.98%
Cash conversion cycle: 159.6 days

About

In plain English

Dr. Reddy's is a global pharmaceutical company that makes both generic and branded medicines, as well as the active ingredients that go into them. For example, they recently launched a generic version of the cancer drug bosutinib in the US, and they were the first to sell a generic semaglutide injection (used for Type 2 diabetes) in Canada. They also sell over-the-counter nutrition products like Celevida GLP+, developed with Nestlé, and partner with other companies to bring critical-care antibiotics and ALS treatments to market. Their customers include hospitals, pharmacies, and governments in North America, Europe, India, and emerging markets like Russia and South Africa. They make money by selling these drugs and ingredients directly to distributors, healthcare providers, and through partnerships.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 22 Jul 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	8,100	7,546	8,753	8,828	8,572	8,528	8,381	8,038	7,696	7,114	7,237	6,903
	354.70	475.40	268.80	323.90	290.30	522.10	150.20	307.50	187.20	197.50	216.20	315.00
	7,902	7,827	7,481	7,414	6,958	7,051	6,661	6,434	6,007	5,710	5,627	5,305
	1,654	1,199	1,826	1,441	2,036	1,716	1,453	1,287	1,227	1,096	1,141	955.90
	1,974	1,658	1,542	1,746	1,216	1,128	1,051	1,283	1,380	1,176	1,208	1,138
	1,652	1,447	1,588	1,452	1,504	1,401	1,366	1,399	1,414	1,284	1,276	1,280
	125.50	105.70	94.40	90.70	83.00	65.60	81.70	75.70	59.80	59.30	39.40	35.30
	536.60	557.10	521.00	504.60	476.10	454.70	471.40	397.00	380.60	367.70	373.50	375.50
	2,203	2,504	2,182	2,243	2,088	2,280	2,161	2,103	—	1,924	—	—
	552.50	195.10	1,541	1,738	1,905	2,000	1,870	1,911	1,877	1,602	1,826	1,912
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	552.50	195.10	1,541	1,738	1,905	2,000	1,870	1,911	1,877	1,602	1,826	1,912
	117.70	-21.60	353.60	408.00	495.10	418.50	470.10	575.50	490.20	295.40	448.20	434.50
	435.60	221.30	1,190	1,337	1,410	1,587	1,404	1,342	1,392	1,310	1,381	1,482
	5.33	2.65	14.53	16.18	17.04	19.12	16.97	15.08	83.61	78.66	82.94	89.09
Key metrics
	1,215	857.90	2,156	2,334	2,464	2,520	2,423	2,384	2,317	2,029	2,239	2,323
	15.00%	11.40%	24.60%	26.40%	28.70%	29.50%	28.90%	29.70%	30.10%	28.50%	30.90%	33.70%
	5.40%	2.90%	13.60%	15.10%	16.40%	18.60%	16.80%	16.70%	18.10%	18.40%	19.10%	21.50%
	—	0.70%	—	4.70%	—	5.70%	—	—	—	—	—	—
	-5.50%	-11.50%	4.40%	9.80%	11.40%	19.90%	15.80%	16.50%	—	—	—	—
	-69.10%	-86.10%	-15.30%	-0.40%	1.30%	21.10%	1.70%	-9.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	33,228	33,700	32,644	28,011	24,670	21,545	19,048	17,517	15,448	14,281	14,196
	1,423	1,358	1,097	894.30	1,056	484.40	291.40	620.60	337.50	155.20	171.50
	30,624	29,679	26,083	21,719	19,714	19,038	16,503	16,308	13,494	13,086	12,814
	6,119	6,501	5,684	4,490	4,220	4,312	4,296	2,985	2,889	2,631	2,193
	6,920	6,162	4,841	4,399	3,367	3,484	2,574	2,546	1,881	1,450	—
	6,139	5,991	5,580	5,030	4,647	3,886	3,630	3,380	3,356	3,215	3,107
	416.30	373.80	282.90	171.10	142.80	95.80	97.00	98.30	88.90	78.80	63.40
	2,119	2,059	1,704	1,470	1,250	1,165	1,229	1,163	1,135	—	1,027
	9,132	9,017	8,537	6,839	—	—	—	—	—	—	3,879
	4,027	5,379	7,658	7,186	6,012	2,991	2,836	1,830	2,292	1,350	1,554
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	4,027	5,379	7,658	7,186	6,012	2,991	2,836	1,830	2,292	1,350	1,554
	857.70	1,235	1,954	1,623	1,541	878.90	931.90	140.30	385.80	438.00	296.50
	3,183	4,158	5,725	5,578	4,507	2,182	1,952	2,026	1,950	912.40	1,257
	38.69	50.41	67.89	335.22	271.47	131.57	117.67	122.22	117.53	—	77.53
Key metrics
	6,563	7,812	9,644	8,827	7,404	4,252	4,161	3,091	3,516	1,429	2,644
	19.75%	23.20%	29.50%	31.50%	30.00%	19.70%	21.80%	17.60%	22.80%	10.00%	18.60%
	9.58%	12.30%	17.50%	19.90%	18.30%	10.10%	10.20%	11.60%	12.60%	6.40%	8.90%
	—	13.90%	21.80%	—	—	—	—	—	—	—	—
	—	3.20%	16.50%	13.50%	14.50%	13.10%	8.70%	13.40%	8.20%	0.60%	—
	—	-27.40%	2.60%	23.80%	106.50%	11.80%	-3.70%	3.90%	113.70%	-27.40%	—
	—	3,343	1,892	—	—	—	—	—	—	—	—
	—	1.36	0.81	—	—	—	—	—	—	—	—
	—	0.16	0.12	—	—	—	—	—	—	—	—
	—	4,757	2,719	—	—	—	—	—	—	—	—
	—	159.6	151.0	—	—	—	—	—	—	—	—
Balance sheet
	—	58,123	49,427	—	—	—	—	—	—	—	—
	—	30,179	25,018	—	—	—	—	—	—	—	—
	—	1,537	1,465	—	—	—	—	—	—	—	—
	—	10,123	9,042	—	—	—	—	—	—	—	—
	—	7,653	7,108	—	—	—	—	—	—	—	—
	—	2,990	2,707	—	—	—	—	—	—	—	—
	—	10,078	7,298	—	—	—	—	—	—	—	—
	—	3,038	2,648	—	—	—	—	—	—	—	—
	—	16,747	13,034	—	—	—	—	—	—	—	—
	—	6,294	4,184	—	—	—	—	—	—	—	—
	—	6,294	3,804	—	—	—	—	—	—	—	—
	—	0.00	380.00	—	—	—	—	—	—	—	—
	—	38,231	33,927	—	—	—	—	—	—	—	—
Cash flow
	—	5,674	4,643	—	—	—	—	—	—	—	—
	—	-6,549	-5,102	—	—	—	—	—	—	—	—
	—	829.00	1,186	—	—	—	—	—	—	—	—
	—	2,331	2,750	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	5,137	3,822	4,283	4,619	7,810	5,563	5,015	6,696	5,841	5,105	4,103	4,839
	440.40	567.20	360.30	364.20	398.30	414.40	235.40	207.60	217.80	212.70	227.60	223.10
	5,080	4,695	4,539	4,466	4,272	4,416	4,131	4,263	4,145	3,978	3,699	3,461
	1,306	1,121	1,067	1,009	1,136	942.60	1,012	934.30	911.10	907.70	818.70	751.20
	902.20	479.00	769.20	723.80	663.80	534.70	508.40	656.50	740.30	546.30	556.90	499.20
	967.00	834.50	960.20	867.90	887.30	797.10	794.40	840.10	855.90	779.50	782.30	783.70
	73.10	54.30	41.40	33.40	19.20	31.10	43.30	28.40	7.10	5.90	5.60	5.80
	317.70	318.50	314.30	294.80	279.80	264.50	265.10	260.00	249.80	246.20	246.40	245.80
	1,566	1,771	1,518	1,540	1,499	1,763	1,545	1,637	—	1,519	—	—
	497.00	-305.50	104.20	516.30	3,936	1,562	1,119	2,641	1,914	1,339	631.90	1,601
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	497.00	-305.50	104.20	516.30	3,936	1,562	1,119	2,641	1,914	1,339	631.90	1,601
	92.30	-86.10	13.60	129.00	975.10	361.10	270.00	758.70	496.70	304.40	156.70	408.00
	404.70	-219.40	90.60	387.30	2,961	1,201	849.40	1,882	1,417	1,035	475.20	1,193
	4.86	-2.63	1.09	4.65	35.59	14.41	10.20	22.60	85.10	62.14	28.55	71.68
Key metrics
	887.80	67.30	459.90	844.50	4,235	1,857	1,428	2,929	2,171	1,591	883.90	1,852
	17.30%	1.80%	10.70%	18.30%	54.20%	33.40%	28.50%	43.70%	37.20%	31.20%	21.50%	38.30%
	7.90%	-5.70%	2.10%	8.40%	37.90%	21.60%	16.90%	28.10%	24.30%	20.30%	11.60%	24.60%
	—	-0.80%	—	1.70%	—	5.40%	—	—	—	—	—	—
	-34.20%	-31.30%	-14.60%	-31.00%	33.70%	9.00%	22.20%	38.40%	—	—	—	—
	-86.30%	-118.30%	-89.30%	-79.40%	108.90%	16.00%	78.70%	57.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	17,860	20,533	23,115	19,484	16,962	14,405	13,349	11,850	10,626	9,359	9,720
	1,732	1,690	1,003	862.30	591.30	482.00	801.10	743.20	238.40	204.00	591.20
	18,780	17,971	16,883	14,555	13,688	12,663	11,094	9,818	9,163	8,866	8,766
	4,503	4,332	3,800	3,292	3,161	3,378	3,266	2,556	2,103	2,011	1,818
	2,874	2,636	2,440	1,987	1,779	2,057	1,252	1,117	868.60	671.60	671.50
	3,630	3,550	3,288	3,086	2,833	2,435	2,270	2,030	1,932	1,843	1,803
	202.20	148.30	109.90	21.80	16.90	38.00	46.70	47.80	56.80	62.80	57.20
	1,245	1,207	1,039	975.60	923.20	814.30	835.00	789.20	780.60	774.10	—
	6,396	6,328	6,380	5,406	—	—	—	—	—	—	—
	812.00	4,251	7,236	5,791	3,866	2,224	3,056	2,776	1,701	697.00	1,544
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	812.00	4,251	7,236	5,791	3,866	2,224	3,056	2,776	1,701	697.00	1,544
	148.80	1,032	1,886	1,449	1,253	600.60	869.80	161.90	423.40	130.10	160.40
	663.20	3,220	5,349	4,342	2,613	1,623	2,186	2,938	1,277	566.90	1,384
	7.97	38.68	64.22	260.95	157.37	97.85	131.84	177.23	76.98	—	83.05
Key metrics
	2,260	5,607	8,385	6,789	4,806	3,076	3,938	3,613	2,538	1,534	1,602
	12.65%	27.30%	36.30%	34.80%	28.30%	21.40%	29.50%	30.50%	23.90%	16.40%	16.50%
	3.71%	15.70%	23.10%	22.30%	15.40%	11.30%	16.40%	24.80%	12.00%	6.10%	14.20%
	—	13.60%	24.80%	—	—	—	—	—	—	—	—
	—	-11.20%	18.60%	14.90%	17.80%	7.90%	12.60%	11.50%	13.50%	-3.70%	—
	—	-39.80%	23.20%	66.20%	61.00%	-25.80%	-25.60%	130.00%	125.30%	-59.00%	—
	—	2,611	1,886	—	—	—	—	—	—	—	—
	—	1.45	0.79	—	—	—	—	—	—	—	—
	—	0.17	0.12	—	—	—	—	—	—	—	—
	—	5,082	3,066	—	—	—	—	—	—	—	—
	—	127.5	134.9	—	—	—	—	—	—	—	—
Balance sheet
	—	43,602	38,291	—	—	—	—	—	—	—	—
	—	18,523	16,503	—	—	—	—	—	—	—	—
	—	337.50	319.70	—	—	—	—	—	—	—	—
	—	4,119	5,959	—	—	—	—	—	—	—	—
	—	4,956	4,576	—	—	—	—	—	—	—	—
	—	2,219	1,964	—	—	—	—	—	—	—	—
	—	7,753	5,865	—	—	—	—	—	—	—	—
	—	1,904	1,993	—	—	—	—	—	—	—	—
	—	11,142	8,652	—	—	—	—	—	—	—	—
	—	5,419	3,386	—	—	—	—	—	—	—	—
	—	5,419	3,386	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	31,366	28,857	—	—	—	—	—	—	—	—
Cash flow
	—	4,660	4,225	—	—	—	—	—	—	—	—
	—	-5,785	-5,698	—	—	—	—	—	—	—	—
	—	1,117	1,591	—	—	—	—	—	—	—	—
	—	2,049	2,339	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.57%
Sales CAGR 5Y: +8.99%
Sales CAGR 10Y: —
Profit CAGR 3Y: +7.21%
Profit CAGR 5Y: +8.05%
Profit CAGR 10Y: —
Sales YoY (TTM): -28.80%
Profit YoY (TTM): -90.38%

Consolidated

Sales CAGR 3Y: +10.96%
Sales CAGR 5Y: +12.09%
Sales CAGR 10Y: —
Profit CAGR 3Y: -2.66%
Profit CAGR 5Y: +16.33%
Profit CAGR 10Y: —
Sales YoY (TTM): -0.87%
Profit YoY (TTM): -44.57%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 26.62%

Holder	Type	Holding	Previous	Change
LIFE INSURANCE CORPORATION OF INDIA - P & GS Fund	Public	12.16%	—	—
GVP Family Trust	Promoter Group	11.51%	—	—
J P Morgan Chase Bank NA	Public	11.41%	—	—
VSD Family Trust	Promoter Group	9.06%	—	—
ICICI PRUDENTIAL VALUE DISCOVERY FUND	Public	4.41%	—	—
KALLAM SATISH REDDY HUF	Promoter	3.31%	—	—
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2	Public	3.15%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND	Public	1.88%	—	—
PARAG PARIKH FLEXI CAP FUND	Public	1.76%	—	—
GUNUPATI VENKATESWARA PRASAD HUF	Promoter	1.52%	—	—
SBI NIFTY INDEX FUND	Public	1.43%	—	—
SATISH REDDY KALLAM	Promoter	1.21%	—	—
GOVERNMENT PENSION FUND GLOBAL	Public	1.08%	—	—
ANURADHA GUNUPATI	Promoter	0.01%	—	—
SNSG Trading Private Limited	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201518 Sep 2026 · Company Update / Press Release / Media Release
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201518 Sep 2026 · Company Update / General
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....17 Sep 2026 · Company Update / Clarification
Copies of newspaper publication16 Sep 2026 · Company Update / Newspaper Publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201511 Sep 2026 · Company Update / General
Allotment of Employee Stock options10 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Analyst meet10 Sep 2026 · Company Update / Analyst / Investor Meet
Allotment of Employee Stock options26 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Copies of newspaper publication20 Aug 2026 · Company Update / Newspaper Publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514 Aug 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Change in Senior Management Personnel13 Aug 2026 · Company Update / Change in Management
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 21057 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 21057 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20157 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Press Release1 Aug 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201529 Jul 2026 · Company Update / General
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201529 Jul 2026 · Company Update / General
Transcript of Earnings call recording28 Jul 2026 · Company Update / Analyst / Investor Meet
The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) ....28 Jul 2026 · Company Update / Clarification
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 201523 Jul 2026 · Company Update / Change in Management
Scrutinizer''s Report23 Jul 2026 · AGM/EGM / AGM
Outcome of 42nd Annual General Meeting23 Jul 2026 · AGM/EGM / AGM
Copy of newspaper publication23 Jul 2026 · Company Update / Newspaper Publication
Intimation of Earnings call recordings23 Jul 2026 · Company Update / Press Release / Media Release
Copy of Investor Presentation22 Jul 2026 · Company Update / Investor Presentation
Grant of Employee Stock Options22 Jul 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201522 Jul 2026 · Company Update / Change in Management
Unaudited Financial results for the quarter ended June 30, 202622 Jul 2026 · Result / Financial Results
Outcome of Board Meeting held on July 22, 202622 Jul 2026 · Board Meeting / Outcome of Board Meeting
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Conference Call Transcript15 Jul 2026 · Company Update / General
Intimation of Earnings call13 Jul 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201510 Jul 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20159 Jul 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20159 Jul 2026 · Company Update / General
Certificate under Reg 74(5) of SEBI (Depositories and Participants), Regulations, 20186 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed copy of Newspaper Publication1 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed copy of Newspaper Publication1 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-2630 Jun 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 8.0000	10 Jul 2026	10 Jul 2026	—
Final Dividend - Rs. - 8.0000	10 Jul 2025	10 Jul 2025	—
Stock Split From Rs.5/- to Rs.1/-	28 Oct 2024	28 Oct 2024	—
Final Dividend - Rs. - 40.0000	16 Jul 2024	—	—

Board meetings

22 Jul 2026 Board Meeting - Financial Results